SEC Form DFiling only, no announcement found
Altay Therapeutics, based in San Carlos, CA, reported $15,738,155 sold in a private offering of equity, with the first sale on September 17, 2026, in a Form D filed with the SEC on October 2, 2026. The filing says 19 investors have already invested. The offering authorizes up to $45,067,885.
Legal name on the filing: Altay Therapeutics, Inc..
| Amount sold | $15,738,155Basis: Form D total amount sold, as of the filing of October 2, 2026. Not the announced round size. |
|---|---|
| Total offering | $45,067,885The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $29,329,730 |
| Securities offered | Equity |
| Exemption claimed | Rule 506(b) |
| Date of first sale | September 17, 2026 |
| Investors already invested | 19 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Biotechnology |
| Principal place of business | San Carlos, CA |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 2157551 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| JAMES BREITMEYER | Executive Officer, Director | None linked |
| ALI OZES | Executive Officer | None linked |
| ERIC BJERKHOLT | Director | None linked |
| MIKE GREY | Director | None linked |
| ESTER SKLARSKY | Director | None linked |
| AIDAN KING | Director | None linked |
| CHELSEA JOHNSON | Director | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Oct 2, 2026 | D (original) | $15,738,155 | $45,067,885 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through October 23, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "Altay Therapeutics: SEC Form D deal record", https://vcbeast.com/deals/altay-therapeutics-form-d-2026-09-17. Source: SEC EDGAR, accession 0002157551-26-000001.